Tycho Peterson - Adaptive Biotechnologies Chief Officer
| ADPT Stock | USD 5.73 0.05 0.88% |
Insider
Tycho Peterson is Chief Officer of Adaptive Biotechnologies Corp
| Age | 50 |
| Address | 1165 Eastlake Avenue East, Seattle, WA, United States, 98109 |
| Phone | 206 659 0067 |
| Web | https://www.adaptivebiotech.com |
Latest Insider Transactions
Tycho Peterson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Tycho Peterson against Adaptive Biotechnologies stock is an integral part of due diligence when investing in Adaptive Biotechnologies. Tycho Peterson insider activity provides valuable insight into whether Adaptive Biotechnologies is net buyers or sellers over its current business cycle. Note, Adaptive Biotechnologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell Adaptive Biotechnologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Tycho Peterson over six months ago Disposition of 64961 shares by Tycho Peterson of Adaptive Biotechnologies at 8.14 subject to Rule 16b-3 |
Adaptive Biotechnologies Management Efficiency
The company has return on total asset (ROA) of (0.1637) % which means that it has lost $0.1637 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6676) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies' management efficiency ratios could be used to measure how well Adaptive Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2024. Return On Capital Employed is likely to drop to -0.42 in 2024. At this time, Adaptive Biotechnologies' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 276.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 84.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| FACC MD | Verve Therapeutics | 61 | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Valerie MD | Elevation Oncology | 46 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Brittany Mccleery | Sana Biotechnology | N/A | |
| Howard Horn | Vir Biotechnology | 46 | |
| MBA JD | Apellis Pharmaceuticals | 51 | |
| John MBA | Beam Therapeutics | 46 | |
| Katherine Tuminello | Krystal Biotech | N/A | |
| Steven Kanner | Caribou Biosciences | 64 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Christopher Hite | Royalty Pharma Plc | 56 | |
| Steven Rice | Vir Biotechnology | 64 | |
| Giuseppe Ciaramella | Beam Therapeutics | 55 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Alfredo Castro | Ikena Oncology | N/A | |
| MBA MD | Ikena Oncology | 59 | |
| Nur Nicholson | Apellis Pharmaceuticals | 54 | |
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.16 |
Adaptive Biotechnologies Leadership Team
Elected by the shareholders, the Adaptive Biotechnologies' board of directors comprises two types of representatives: Adaptive Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adaptive. The board's role is to monitor Adaptive Biotechnologies' management team and ensure that shareholders' interests are well served. Adaptive Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adaptive Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yi Zhou, Chief Officer | ||
| Tycho Peterson, Chief Officer | ||
| Stacy JD, General VP | ||
| Harlan Robins, Co-Founder, Chief Scientific Officer | ||
| Kyle Piskel, Principal Officer | ||
| Susan Bobulsky, Chief MRD | ||
| Stacy Taylor, General VP | ||
| Mark Adams, Chief Officer | ||
| Julie Rubinstein, President COO | ||
| Francis Lo, Chief Officer | ||
| Sharon Benzeno, Chief Medicine | ||
| Karina Calzadilla, Vice Relations | ||
| Chad MBA, CEO CoFounder | ||
| Nitin Sood, Chief MRD | ||
| MBA MBA, CEO CoFounder | ||
| Mary Lancelotta, Senior BioPharma | ||
| Christopher Carlson, Founder |
Adaptive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adaptive Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 694.13 M | ||||
| Shares Outstanding | 147.58 M | ||||
| Shares Owned By Insiders | 1.92 % | ||||
| Shares Owned By Institutions | 93.97 % | ||||
| Number Of Shares Shorted | 8.2 M | ||||
| Price To Earning | 0.25 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.